Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00612898Phase 2Terminated

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

Role: lead

NCT00367952Phase 2Completed

A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

Role: lead

NCT00126880Phase 2Completed

AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

Role: lead

NCT00334659Phase 1Completed

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

Role: lead

NCT00686270Phase 3Withdrawn

A Long Term Safety Study of Apricitabine in HIV-infected Patients

Role: lead

NCT00352066Phase 1Completed

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

Role: lead

All 6 trials loaded